A Review of the Network Meta-Analysis and Psoriasis Management

Authors

  • Anastasiya Muntyanu, MD, PhD, FRCPC, FAAD Women's College Hospital, Toronto, ON Canadian Dermatology Center, Toronto, ON

DOI:

https://doi.org/10.58931/cdt.2025.6s01138

Abstract

Clinical trials are the gold standard for evaluating safety and efficacy of new therapeutics and guiding our treatment decisions. However, with the rapid development of new therapeutics in dermatology, we increasingly need additional tools to inform our overall approach to patient care. Previously, meta‐analyses were used to evaluate the results of several randomized controlled trials (RCTs). However, they were limited to comparing 2 interventions at a time. Recently, network meta‐analysis (NMA) has emerged as a new tool allowing simultaneous comparison of 3 or more interventions by incorporating both direct comparisons from head‐to‐head trials and indirect evidence drawn from studies that share a common comparator (e.g. placebo or active control).

Author Biography

Anastasiya Muntyanu, MD, PhD, FRCPC, FAAD, Women's College Hospital, Toronto, ON Canadian Dermatology Center, Toronto, ON

Dr. Anastasiya Muntyanu is a Canadian and US board-certified dermatologist, currently practicing in Toronto. She completed her medical school at the University of Ottawa and graduated from the University of Toronto Dermatology Residency Program. She is completing her PhD focused on studying environmental triggers of autoimmune and inflammatory skin diseases including psoriasis, systemic sclerosis, atopic dermatitis. She has over 40 publications in high impact journals and has received numerous awards including from the Canadian Institutes of Health Research award, Canadian Dermatology Association, and American Dermato-Epidemiology Network.  During her residency she was the co-chair of the Canadian Dermatology Association’s Resident and Fellow Society and was a resident representative on numerous academic committees for which she received the Resident Leadership Award and the Resident Teaching Award from the Canadian Dermatology Association. Dr. Muntyanu’s clinical areas of interest include medical and surgical dermatology with a focus on psoriasis, eczema, systemic sclerosis and morphea, and skin cancer.

References

Brignardello-Petersen R, Guyatt GH. Introduction to network meta-analysis: understanding what it is, how it is done, and how it can be used for decision-making. Am J Epidemiol. 2024. doi:10.1093/aje/kwae260

Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103-111. doi:10.1007/s11739-016-1583-7

Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1):159. doi:10.1186/1741-7015-11-159

Florez ID, De La Cruz-Mena JE, Veroniki AA. Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists. J Clin Epidemiol. 2024;176:111537. doi:10.1016/j.jclinepi.2024.111537

Singh J, Gsteiger S, Wheaton L, Riley RD, Abrams KR, Gillies CL, et al. Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials. BMC Med Res Methodol. 2022;22(1):186. doi:10.1186/s12874-022-01657-y

Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol. 2022;191(5):930-938. doi:10.1093/aje/kwab278

Phillips MR, Steel DH, Wykoff CC, Busse JW, Bannuru RR, Thabane L, et al. A clinician's guide to network meta-analysis. Eye (Lond). 2022;36(8):1523-1526. doi:10.1038/s41433-022-01943-5

Lunny C, Veroniki A-a, Higgins JPT, Dias S, Hutton B, Wright JM, et al. Methodological review of NMA bias concepts provides groundwork for the development of a list of concepts for potential inclusion in a new risk of bias tool for network meta-analysis (RoB NMA Tool). Syst Rev. 2024;13(1):25. doi:10.1186/s13643-023-02388-x

Guelimi R, Afach S, Régnaux JP, Bettuzzi T, Chaby G, Sbidian E, et al. Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality. Br J Dermatol. 2022;187(1):29-41. doi:10.1111/bjd.20908

Augustin M, Valencia Lopez M, Reich K. Network meta-analyses in psoriasis: overview and critical discussion. J Eur Acad Dermatol Venereol. 2021;35(12):2367-2376. doi:10.1111/jdv.17650

Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. doi:10.1002/14651858.CD011535.pub6

Armstrong A, Fahrbach K, Leonardi C, Augustin M, Neupane B, Kazmierska P, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777-1792. doi:10.1007/s13555-022-00760-8

Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, et al. Long-term benefit–risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Derm Ther (Heidelb). 2022;12(1):167-184. doi:10.1007/s13555-021-00647-0

Downloads

Published

2025-04-09

How to Cite

1.
Muntyanu A. A Review of the Network Meta-Analysis and Psoriasis Management. Can Dermatol Today [Internet]. 2025 Apr. 9 [cited 2025 May 9];6(s01):2–7. Available from: https://canadiandermatologytoday.com/article/view/6-s01-Muntyanu

Issue

Section

Articles